86. Pulmonary arterial hypertension Clinical trials / Disease details

Clinical trials : 1,205 / Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04266197 (ClinicalTrials.gov)	September 25, 2020	22/1/2020	Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study	A Phase 2b, Open-label, Single Dose Study to Evaluated the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects With Pulmonary Arterial Hypertension (PAH)	Pulmonary Arterial Hypertension	Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)	Respira Therapeutics, Inc.	NULL	Recruiting	18 Years	80 Years	All	86	Phase 2	United States;Serbia
2	NCT05343637 (ClinicalTrials.gov)	July 30, 2019	4/4/2022	A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension	A Phase 2a, Dose Escalation Study to Evaluate the Effect of RT234 on Cardiopulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Combination Product: Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)	Respira Therapeutics, Inc.	NULL	Completed	18 Years	80 Years	All	14	Phase 2	Australia